NEW YORK (AP) ¿ Life sciences companies that depend on research dollars from big pharma could see a downturn in contracts if pharmaceutical companies continue buying each other and cutting costs. On Monday, Whitehouse Station, N.J.-based Merck & Co. said it is buying Kenilworth, N.J.-based Schering-Plough Corp. for $41.1 billion in the latest industry consolidation. Earlier this year, New York-based Pfizer Inc. said it would buy Madison, N.J.-based Wyeth for $68 billion. In each case, the companies making the acquisitions are looking to shore up their development pipelines while saving operating costs, which includes research and development. In a note to clients late Monday, Thomas Weisel Partners analyst Peter Lawson said the latest buyouts could pressure other companies to combine as they lose patent protection on blockbuster drugs and see generic competition cut into revenue. "We believe research and development cost cutting would serve to reduce visibility for capital spending by pharma in the short term," he said. He said Merck spent about $4.68 billion in research and development in 2008 while Schering-Plough spent about $3.52 billion. He had expected biopharma research and development growth of 4.3 percent in 2010, but that could be limited to 2.2 percent because of the Pfizer-Wyeth deal. Considering both the Pfizer-Wyeth deal and the merger of Merck and Schering-Plough, growth could be less than 1 percent.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Replay: Jim Cramer on Earnings Season, China and Amazon Prime Day
Jim Cramer's breaking down what he expects from earnings season, China's slowing growth, and Amazon's Prime day sale.
Prime Day Isn't Just For Amazon -- Target, Walmart, Others Want a Piece Too
Amazon's retail competitors will see a 79% revenue lift around Prime Day, according to a projection from Adobe Analytics.
Jim Cramer: Even if Slowdown Hits, You'll Look Good With These Six Stocks
Estee Lauder is among the companies that are sure winners, now matter which way the economy goes.
Slack Rallies by 3% as Research Firms Initiate Bullish Coverage
Canaccord, Barclays and William Blair all published bullish notes on the messaging service, which went public via a direct listing in June.
Earnings to Soon Give Insight into Market's Strength
Are we seeing low-volume consolidation setting stage for thrust higher or is this stalling action suggesting a rollover? The answer depends on how earnings season develops.